

# Transdermal slow release fentanyl patches for the management of post-operative analgesia following major abdominal surgery: a systematic review.

Countess of Chester Hospital NHS Foundation Trust
S Roy Mahapatra



# Introduction

- ERAS
- Recovery milestones
- Optimal pain relief
- Multimodal analgesia
- PCA
- Transdermal patches



#### **Methods**


- Electronic searches were performed on five major databases from inception to October 2015 to identify relevant studies.
- Eligibility decisions, methodological quality, data extraction, and analysis were performed according to predefined clinical criteria and endpoints.
- 2 reviewers



#### Systematic review

#### Inclusion criteria:

- RCT/n-RCTs
- Major abdominal surgery GI, Gynae, Urology
- Open and Laparoscopic





- Orthopaedic studies
- Animal studies
- PCA transdermal fentanyl
- Chronic pain studies



#### End points

- Primary outcome
  - to determine the reduction in pain score in the patients who received TDF.
- Secondary outcomes
  - to determine reduction in use of supplementary analgesia
  - evaluate adverse effects (a) respiratory depression & requirement for reversal
     (b) gastro-intestinal side effects.



#### Paper Demographics

Characteristic	Number
Total number of patients	730
Placebo	279
Fentanyl patch 25mcg	102
Fentanyl patch 50mcg	156
Fentanyl patch 75mcg	88
Age	44.1 ± 6.6
Male	103 ± 22.3



## Paper demographics


Author	Year	RCT	Blinding	Number	Type of surgery
Hosseini	2015	У	double	120	<b>Exploratory Laparotomy</b>
Seravino	1992	У	double	95	Abd Gynae Surgery
Broome	1995	У	double	82	Abd Hysterectomy
Miguel	1995	У	double	143	Expl Gynea Laparotomy
Lehmann	1991	У	double	50	Urological
Gourlay	1990	У	double	40	Abdominal
Sandler	1994	У	double	120	Abd Hysterectomy
Lehmann	1997	n	no	40	Abdominal
Rowbothan	1989	У	double	40	Upper Abdominal




# Paper Demographics

Author	Time of application	Duration of application (hrs)	induction agent include fentanyl?	Intra- operative iv fentanyl?	supplementary analgesia
Hosseini	pre-op 10 hrs	36	y (2µg/kg)	У	iv morphine
Seravino	pre-op 1 hr	48	n	n	iv morphine
Broome	pre-op 2 hrs	72	y (150µg)	n	iv morphine
Miguel	pre-op 1 hr	24	y (5µg/kg)	n	iv morphine
Lehmann	pre-op 8 hrs	24	n	У	iv fentanyl
Gourlay	Intra-op 10min	24	n	У	iv pethidine
Sandler	pre-op 2 hrs	72	n	У	iv morphine
Lehmann	pre-op 1 hr	NR	NR	NR	iv morphine
Rowbothan	pre-op 2 hrs	48	y (200µg)	n	iv morphine

#### Pain score




#### Supplementary morphine usage (24-36hrs post op)



# Gastro-intestinal side effects – post operative vomiting

Odds Ratio			Odds Ratio			
Study or Subgroup	M-H, Random, 95% CI		M-H, Random, 95% CI			
Gourlay	3.00 [0.51, 17.74]					
Hosseini	2.06 [0.83, 5.12]		<del>                                     </del>			
Lehmann	2.42 [0.40, 14.69]		-			
Miguel	0.73 [0.31, 1.76]					
Sandler	1.50 [0.70, 3.21]					
Seravino	2.04 [0.85, 4.88]					
Total (95% CI)	1.52 [0.86, 2.66]		•			
Total events						
Heterogeneity: Tau² = Test for overall effect	= 0.07; Chi² = 3.76, df = 3 (P = 0.29); l² = 20% : Z = 1.45 (P = 0.15)	0.05	0.2 1 5 20 Favours TDF Favours placebo			

### Respiratory depression



- 10 patients required reversal of opioids with naloxone (2.2% in red)
- 50% of those reversed receive the 75mcg patch
- 0 patients in the placebo group required naloxone



#### Discussion

- TDF is effective and safe
- Lack of evidence in lower GI surgery
- Lack of knowledge on GI side effects
- Requires high-powered randomised controlled trials to evaluate further



#### Acknowledgements and Thanks

• The Colorectal Team and Anaesthetic Team at the Countess of Chester